ABBV•benzinga•
AbbVie, EvolveImmune Therapeutics Announce Option-To-License Agreement; EvolveImmune To Receive $65M In Aggregate Upfront Fees And Equity Investment From AbbVie; AbbVie Eligible For Up To $1.4B In Option Fees, Milestones
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on October 31, 2024 by benzinga